Spotify Technology (NYSE:SPOT) Q4 2025 Earnings call February 10, 2026 08:00 AM ET Speaker5Good day, and welcome to Spotify's fourth quarter 2025 earnings call and webcast. All participants are in a listen-only mode. If you require operator assistance at any time, please press star zero. As a reminder, this conference call is being recorded. I would now like to turn the call over to Bryan Goldberg, Head of Investor Relations. Thank you. Please go ahead.Speaker1Thanks, operator, and welcome to Spotify's four ...

Group 1 - The company emphasizes the importance of talent incentives and long-term value creation [1] - The company will actively assess the feasibility of equity incentives when conditions are mature and align with strategic development needs [1]

Financial Data and Key Metrics Changes - Adjusted EPS for Q4 2025 was $1.53, up 21% year-over-year, driven by a 5.4% core sales growth [6][30] - Full-year adjusted EPS increased by 24%, supported by strong team performance and investments in advanced technologies [6] - Core FX neutral backlog increased by 14% year-over-year, indicating strong demand [30] Business Line Data and Key Metrics Changes - Aerospace and Advanced Technologies segment sales reached $272 million, a 15% increase, primarily organic [31] - Process Flow Technologies segment sales were $309 million, flat compared to the previous year, with core sales down 1.5% [32][20] - Adjusted segment margin for Aerospace and Advanced Technologies expanded to 23.6%, up 50 basis points from the previous year [32] Market Data and Key Metrics Changes - Commercial OEM sales increased by 27%, while military OEM sales rose by 18% [32] - Total aftermarket sales increased by 1%, with commercial aftermarket sales up 3% and military aftermarket down 3% [32] - Core FX neutral orders in Process Flow Technologies decreased by 3%, driven by weaker chemical end markets [32] Company Strategy and Development Direction - The company aims for 4%-6% core sales growth and 35%-40% core operating leverage, with a focus on delivering shareholder value [5] - Recent acquisitions, including Druck, Panametrics, and Reuter-Stokes, are expected to enhance growth and support existing and new customers [6][9] - The company plans to expand its Aerospace and Advanced Technologies segment by exploring adjacent markets and technologies [8][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength and resilience of the company’s team and portfolio, anticipating strong performance in 2026 [11] - The company expects core sales growth for Aerospace and Advanced Technologies to be at the high end of the 7%-9% long-term growth assumption [16] - Management noted that while the chemical market remains sluggish, other segments like pharmaceuticals and cryogenics are expected to grow [20][56] Other Important Information - The company will exclude non-cash, tax-affected, acquisition-related intangible amortization from its non-GAAP presentation of adjusted EPS starting in 2026 [12][34] - The integration process for recent acquisitions is underway, with expectations for these businesses to be slightly accretive to earnings in 2026 [22] Q&A Session Summary Question: What are the pricing opportunities at Druck in 2026 and 2027? - Management indicated significant pricing opportunities and expects improvements starting this year, with no obstacles to achieving goals [40][41] Question: Can you clarify guidance related to cost takeout at PSI? - Management confirmed that there are no changes to previously discussed cost takeout expectations, which remain consistent with earlier communications [42][43] Question: Can you discuss the strategic direction of the renamed AAT segment? - Management explained that the renaming allows for expansion into adjacent technologies and markets, similar to previous successful strategies [52][53] Question: What is the outlook for the chemical market in 2026? - Management expects the chemical market to remain sluggish, with no strong uptick anticipated, but is prepared to capitalize on any opportunities [56][58] Question: What are the expected synergies from the PSI acquisitions? - Management indicated that while initial synergies may be modest, they expect significant improvements in margins and performance in the coming years [95][96]

在投资领域，中国人寿海外公司投资策略注重风险管理和长期价值创造，为中国香港国际金融中心的可 持续发展注入强劲动力。 据了解，2025年11月香港特区政府发行多币种数码绿色债券，包括美元债、离岸人民币债、港元债及欧 元债。中国人寿海外公司参与全部四个币种债券认购，合计约24亿等值港元，成为中资保险最大认购 方。 2025年，中国人寿海外公司参与了多宗香港H股IPO，支持联交所18A章程（允许未盈利生物科技公司 上市），积极投资半导体、AI、医疗等热点领域企业，支持优秀中资企业在IPO中获得合理定价。 据悉，中国人寿海外公司还通过半导体、AI、医疗等赛道的多只私募股权基金，积极参与到多个明星 创新企业的股权投资，其中包括2025年9月在香港联交所主板挂牌上市的禾赛科技（02525.HK），2026 年1月在香港联交所挂牌上市的"AI大模型第一股"——MiniMax（00100.HK）。 （文章来源：中国经营报） 2026年1月20日，《中国经营报》记者从中国人寿集团获悉，截至2025年12月31日，中国人寿海外公司 总资产已超过4528亿港元。 ...

Core Insights - The article highlights the transformation of the dental healthcare industry in China, emphasizing the shift from rapid expansion to value-driven operations, with 瑞尔齿科 (Rui'er Dental) exemplifying this change through its long-term patient relationships and commitment to quality care [1][7]. Group 1: Company Development - 瑞尔齿科 has evolved from its first clinic in 1999 to a nationwide network of 118 clinics and hospitals across 15 cities, reflecting the industry's transition from extensive growth to refined operations [1]. - The company has achieved a patient revisit rate of approximately 47.4%, with nearly 20% of new patients coming from referrals by existing patients, indicating strong trust and satisfaction [2][3]. Group 2: Quality and Trust - The foundation of 瑞尔齿科's value system is its unwavering commitment to medical quality, utilizing a multidisciplinary treatment model and a tiered quality control system to establish a professional moat beyond mere scale [2]. - The introduction of the "5A customer experience process" emphasizes a comprehensive approach to patient care, focusing on sustainable relationships rather than one-time transactions [3]. Group 3: Digital Transformation - 瑞尔齿科 is integrating artificial intelligence into its core operations, developing an AI quality control system that performs comprehensive checks on electronic medical records, enhancing both efficiency and quality [4]. - The company is also exploring innovative AI applications, such as an "AI operations director" and "AI family health manager," to support management decisions and improve patient interactions [4]. Group 4: Industry Influence - 瑞尔齿科's impact extends beyond its own growth, as it organizes numerous academic and management training sessions, reaching tens of thousands of healthcare professionals, thereby creating a systematic knowledge output framework [5]. - The company hosts high-level academic forums and diverse training programs, converting its extensive experience into replicable industry knowledge, promoting standardization in dental healthcare services [6]. Group 5: Long-term Strategy - 瑞尔齿科 prioritizes depth of service and patient satisfaction over rapid expansion, focusing on building brand reputation through quality care rather than marketing expenditures [6]. - The company's long-term approach has been validated financially, with high revisit rates reducing customer acquisition costs and enhancing operational efficiency, creating a virtuous cycle of commercial and social value [6][7].

Core Viewpoint - The announcements from Pag Biotech-B (02625) reflect a dual approach of "confidence" and "aggression," with cornerstone shareholders extending their lock-up period to express long-term confidence, while simultaneously initiating a placement to raise funds for future growth [1][2]. Group 1: Cornerstone Shareholder Lock-Up - Cornerstone investors have voluntarily extended their lock-up period for the second time, now until April 30, 2024, indicating strong confidence in the company's R&D capabilities and progress towards significant clinical milestones [2]. - This extension signifies that cornerstone investors are not merely financial speculators but are committed industry capital or long-term value investors, willing to sacrifice liquidity to support the company's growth [2]. - The timing of the lock-up extension suggests it may coincide with key R&D milestones or potential international collaborations, reflecting the investors' expectations for positive developments [2]. Group 2: Fundraising Strategy - Pag Biotech plans to raise nearly HKD 300 million through a placement at HKD 58.41 per share, with several well-known institutions acting as joint placement agents [3]. - The funds are earmarked for strategic development rather than immediate financial relief, with a focus on four key areas: digital transformation in R&D, financial health, pipeline sustainability and internationalization, and operational reserves [3][4]. - The first area, digital transformation, will consume HKD 118 million (40% of the total), focusing on building an AI drug discovery platform, a unified database for competitive analysis, and a digital patient platform to enhance drug adherence and collect real-world data [3][4]. Group 3: Financial Health and International Expansion - The second area, financial health, will account for 28% of the funds, aimed at repaying bank loans to reduce interest expenses and optimize financial statements, thereby enhancing the company's resilience during industry downturns [4]. - The third area focuses on ensuring the continuous development of pipeline products PB2301/PB2309 and establishing a subsidiary in Hong Kong to facilitate global expansion, indicating a proactive approach to international collaboration opportunities [4][5]. - The final area, operational reserves, will utilize 10% of the funds to prepare for the upcoming commercialization phase, ensuring the company is well-equipped for future market challenges [5]. Group 4: Overall Strategic Vision - The combination of the fundraising initiative and the cornerstone investors' support creates a synergistic effect, reducing uncertainties associated with the placement and shifting market focus from short-term dilution to long-term value creation [7]. - This strategic approach indicates that the management is not only focused on immediate clinical data but is also considering systematic improvements in overall innovation efficiency and global competitiveness [6].

Core Viewpoint - The company emphasizes its commitment to long-term value creation and plans to continue optimizing its shareholder return mechanism while sharing growth dividends with investors [1] Group 1 - Since its listing, the company has adhered to the principle of long-term value creation [1] - The company aims to continuously reward investors through excellent operating performance [1] - The company seeks sustainable win-win development with shareholders [1]

PresentationBaard Erik Haugen Good morning, everyone, and welcome to Hydro's Investor Day 2025. My name is Baard Erik Haugen. And together with my colleagues, Martine Rambøl Hagen, Elitsa Blessi, Mathias Gautier, and Camilla Gihle, I'm responsible for Investor Relations in Hydro. We are very happy to see so many of you here in the room with us in London and also a warm welcome to everyone following on the webcast. The topic for this year's Investor Day is strategic discipline, securing long-term value crea ...

Core Viewpoint - The public fund industry in China is undergoing a transformation aimed at high-quality development, with Shenzhen leading the charge through comprehensive reforms and initiatives to enhance the industry’s ecosystem and investor protection [1][2]. Group 1: Industry Reform and Development - The key to high-quality development in the public fund industry lies in reshaping the industry ecosystem and establishing a robust investor interest community among investors, fund managers, sales institutions, and evaluation agencies [2]. - Shenzhen has implemented a systematic work plan covering pre-emptive guidance, mechanism construction, and post-evaluation to promote comprehensive reforms in the industry [1][2]. - As of September, Shenzhen public fund companies have issued 14 floating fee rate products with a total scale of 148.72 billion, and the self-purchase of existing funds reached 219.81 billion, reinforcing the investor interest community [2][3]. Group 2: Fee Reduction and Investor Engagement - Since the fee rate reform in July 2023, 31 public fund companies in Shenzhen have significantly reduced management and custody fees, resulting in over 6 billion in benefits to investors [3]. - The industry is enhancing investor satisfaction through improved customer service systems and educational platforms, with 7 pilot fund advisory companies serving approximately 363,700 clients and managing assets of 15.41 billion [3]. Group 3: Long-term Investment and Research Capability - Shenzhen is focusing on enhancing long-term capital inflow and institutional research capabilities to create a new value ecosystem, with a collaborative mechanism established among various regulatory and financial bodies [4][5]. - As of September, the scale of pension products managed by Shenzhen public fund companies exceeded 2 trillion, growing over 10% from the previous year [5]. - The equity fund scale in Shenzhen reached 2.13 trillion, with a year-to-date growth of 23%, while index funds grew by 31% this year, indicating a robust investment environment [5]. Group 4: Product Innovation and Strategic Alignment - Shenzhen public fund companies are actively innovating products to support national strategies, focusing on technology innovation, pension products, and green finance [7][8]. - By the end of September, the number of technology-themed funds reached 495, with a total scale of 506.09 billion, reflecting a 60.94% increase from the previous quarter [7]. - The scale of green-themed funds reached 112.33 billion, with a quarter-on-quarter growth of 22.33%, demonstrating a commitment to sustainable development [8]. Group 5: Future Directions and Regulatory Focus - Moving forward, Shenzhen's regulatory bodies emphasize risk prevention, strong regulation, and promoting high-quality development while enhancing institutional governance and compliance [9][10]. - The industry aims to continue contributing to the construction of a financial powerhouse by focusing on long-term investments and deepening investor protection [10].

Core Insights - The company is focused on long-term value creation for shareholders through various opportunities [2] - The CEO provided an update on the progress made by the global team and expressed excitement about future prospects [2] Financial Overview - For the full year 2024, the company generated approximately $3.4 billion in global revenues [3]